John Davis, writing on Friday for the InVivo "Deals of the Week" column, was absolutely spot-on -- in his analysis of the Lundbeck/Merck deal -- on Saphris®/Sycrest® (chemical name: asenapine):
. . . .With a large number of atypical antipsychotics competing for attention, any new entrant will have an uphill battle to gain traction. . . . [New Merck] has licensed to CNS-specialist H. Lundbeck exclusive commercialization rights to its recently approved Sycrest (asenapine) for all markets outside of the US, China and Japan. The Danish company paid an undisclosed upfront fee for the rights, and will also make product supply payments to the US company. Asenapine was launched in the US as Saphris by Merck last year, for schizophrenia and for mania associated with bipolar disorder, but has so far disappointed. Making matters trickier in the EU, the schizophrenia indication was turned down in there because regulators were not convinced of the agent's clinical effectiveness. . . .
Indeed -- much the same -- as we wrote, on Tuesday, past.